Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

TR-1

14 Jun 2024 14:10

RNS Number : 5568S
NetScientific PLC
14 June 2024
ย 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BN4R5Q82

Issuer Name

NetScientific PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

James Robert Kight

City of registered office (if applicable)

Hale

Country of registered office (if applicable)

England

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

ย 

City of registered office (if applicable)

ย 

Country of registered office (if applicable)

ย 

5. Date on which the threshold was crossed or reached

14-June-2024

6. Date on which Issuer notified

14-June-2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

3.07402

0.000000

3.07402

736,100

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BN4R5Q82

736,100

3.07402

Sub Total 8.A

736,100

3.07402

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

ย 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

ย 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

ย 

10. In case of proxy voting

Name of the proxy holder

ย 

The number and % of voting rights held

ย 

The date until which the voting rights will be held

ย 

11. Additional Information

ย 

12. Date of Completion

14-June-2024

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ย 
END
ย 
ย 
HOLUSRORSBUNAAR
Date   Source Headline
30th Nov 20201:56 pmRNSEMV Capital leads a £1.28m investment in SageTech
19th Nov 20207:00 amRNSProAxsis appoints DiaPharma as distributor
11th Nov 20202:10 pmRNSPDS updates on Versamune based COVID-19 vaccine
10th Nov 202012:47 pmRNSPDS Biotech Initiates VERSATILE-002 Phase 2 Trial
27th Oct 20209:46 amRNSPDS Announces Initiation of PDS0101 Phase 2 Trial
16th Oct 20207:00 amRNSNetScientific acquires 100% of portfolio company
30th Sep 20209:08 amRNSDirector/PDMR Shareholding
30th Sep 20209:07 amRNSHolding(s) in Company
30th Sep 20208:58 amRNSHolding(s) in Company
25th Sep 202012:37 pmRNSGrant of Options to Director
24th Sep 20207:00 amRNSInterim Results
2nd Sep 20207:00 amRNSHolding(s) in Company
2nd Sep 20207:00 amRNSHolding(s) in Company
24th Aug 202011:28 amRNSResult of General Meeting
21st Aug 20201:23 pmRNSHolding(s) in Company
21st Aug 202011:47 amRNSIssue of Equity
14th Aug 202010:48 amRNSPDS Announces Closing of $19m Offering
12th Aug 202012:28 pmRNSSofant secures £2.3m funding led by EMV Capital
12th Aug 20207:00 amRNSPDS Announces Pricing of $16.5m Common Stock Offer
11th Aug 202012:27 pmRNSPDS Announces Proposed Offering of Common Stock
7th Aug 20209:32 amRNSPosting of shareholder circular
6th Aug 20202:00 pmRNSHolding(s) in Company
5th Aug 202010:32 amRNSResult of Placing
5th Aug 20208:30 amRNSProposed acquisition and placing
4th Aug 202011:05 amRNSSecond Price Monitoring Extn
4th Aug 202011:00 amRNSPrice Monitoring Extension
27th Jul 20203:06 pmRNSPDS Announces Preclinical Data for PDS0203
14th Jul 20204:20 pmRNSPDS collaborator awarded grant for Versamune
29th Jun 20207:00 amRNSG–Tech Medical completes $6.7m Series A financing
25th Jun 20204:41 pmRNSSecond Price Monitoring Extn
25th Jun 20204:35 pmRNSPrice Monitoring Extension
24th Jun 20205:58 pmRNSHolding(s) in Company
24th Jun 20205:54 pmRNSHolding(s) in Company
24th Jun 20204:09 pmRNSResult of AGM
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
18th Jun 202011:05 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
18th Jun 20209:05 amRNSSecond Price Monitoring Extn
18th Jun 20209:00 amRNSPrice Monitoring Extension
18th Jun 20207:00 amRNSPDS & Farmacore Announce Co-Development-PDS0204
15th Jun 20202:41 pmRNSPDS Announces Initiation of Phase 2 Trial PDS0101
8th Jun 20204:42 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
5th Jun 20209:14 amRNSPDS Announces Trial of its Lead Product, PDS0101
1st Jun 20207:00 amRNSNotice of AGM
13th May 20202:46 pmRNSPDS Reports Results for Q1 2020 & Business Update
1st May 202011:33 amRNSConfirmation of Board Changes
30th Apr 202012:06 pmRNSPDS expands CRADA with National Cancer Institute
27th Apr 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.